Reduced Dose Intensity of Daunorubicin During Remission Induction for Low-Risk Patients With Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Chinese Children’s Cancer Group

It is urgently necessary to reduce the adverse effects of chemotherapy while maintaining their cure high rates for children with acute lymphoblastic leukemia (ALL). The present study aimed to determine whether the dose intensity of daunorubicin during the remission-induction phase could be reduced f...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Yong, Wu, Kefei, Zhu, Xiaofan, Cai, Jiaoyang, Hu, Shaoyan, Gao, Ju, Jiang, Hua, Zhai, Xiaowen, Tian, Xin, Fang, Yongjun, Jin, Runming, Hu, Qun, Jiang, Hui, Wang, Ningling, Sun, Lirong, Leung, Wing Kwan, Yang, Minghua, Pan, Kaili, Wu, Xuedong, Liang, Changda, Shen, Shuhong, Yu, Jie, Ju, Xiuli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209708/
https://www.ncbi.nlm.nih.gov/pubmed/35747795
http://dx.doi.org/10.3389/fonc.2022.911567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209708/
https://www.ncbi.nlm.nih.gov/pubmed/35747795
http://dx.doi.org/10.3389/fonc.2022.911567

Ejemplares similares